Jim Cramer's Top Takeaways: Esperion Therapeutics, Platform Specialty Products
Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
NEW YORK (TheStreet) -- Did you miss last night's "Mad Money" on CNBC? If so, here are Jim Cramer's top takeaways for today's trading.
Esperion Therapeutics (ESPR) - Get Report: In an exclusive interview, Cramer spoke with Tim Mayleben, president and CEO of Esperion, to learn just how excited the company is about its anti-cholestrol drug, currently named ETC-1002.
Mayleben said while the drug has a terrible name, it's one of the most attractive drugs under development today, one that is both safe and well tolerated and can reduce bad cholesterol either by itself or in conjunction with a statin.
Perhaps the most exciting feature of ETC-1002 is it comes in a once-daily pill, not an injection that typically involves a trip to a doctor's office. Mayleben said patients overwhelmingly prefer a pill over an injection.
Cramer agreed, saying Esperion's stock is not done going higher as this revolutionary drug could easily be worth billions of dollars.
^SPX data by YCharts
In the "Off The Charts" segment, Cramer went head to head with Real Money colleague Carly Garner over the direction of the markets, using the S&P 500 as her guide.
Garner noted that historically, the period between March 15 and the end of April has been very good for the markets, rising 13 of the past 15 years. But seasonality aside, the S&P is looking good, with a strong floor of support at 2,040, a level that was tested, and held, last week. Garner felt a rally to the 2,170 or 2,180 level was certainly possible, a level at which profit taking would be advised.
Cramer agreed with Garner that the bull appears to be alive and well, despite what seems like daily, and sometimes hourly, volatility.
Platform Specialty Products (PAH) - Get Report: In a second exclusive interview, Cramer spoke with Dan Leever, president and CEO of Platform Specialty, a company that acquires high-cash-flow businesses that are people oriented, ones that provide high levels of service that afford a sustainable advantage.
Leever said while Platform is a U.S.-centric company, it trades in 180 currencies around the globe.
Leever made a bold $200 price target for his now $26 stock, noting that Platform will be looking to issue more equity as it makes its next acquisition.
To read a full recap of "Mad Money" on CNBC, click here.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.
At the time of publication, Cramer's Action Alerts PLUS had no position in stocks mentioned.